Target Identification Service
Target identification initiates the journey of drug development. On the way to identify a target, two types of approaches are applied to bridge the gap between drugs and diseases: target-based or phenotype-based approaches are available, according to different preconditions. Our company provides you with diverse approaches to speed up your drug development in Autoimmune Diseases & Inflammation.
Target-based Approach
Target-based approach is a long-standing drug discovery strategy that relies on a deep understanding of biological targets and relevant knowledge accumulated from genetics and molecular biology. Within this conventional drug discovery scenario, the goal here is to screening drugs that target malfunctioned gene products or signaling pathways with known function in autoimmune and inflammatory diseases.
Phenotype-based Approach
Target identification can be performed when it is established that off-the-shelf drugs have positive effects on cell models or animal models associated with Autoimmune Diseases & Inflammation, but their exact targets of action is undetermined yet. This approach is proved to have greater potential for successful translation in developing first-in-class drugs.
Fig.1 Target-based drug discovery versus phenotype-based drug discovery (Ha J., et al., 2021)
Target identification increases the chances of discovering novel drugs and also facilitates the uncovering of therapeutic mechanism. Target-based and phenotype-based strategies should complement each other, rather than exist in isolation, and jointly promote the accuracy and efficiency of drug development for Autoimmune Diseases & Inflammation.
Our Services
Target identification is the cornerstone of drug discovery and development. Our company provides you with experienced team and necessary resources to support the small molecule drugs development for Autoimmune Diseases & Inflammation. Our services include but are not limited to:
Target-based Approach
We provide this strategy to screen the inhibitors and antagonists of various pro-inflammatory factors.
- Enzymes Cyclooxygenases
ROS-generating enzymes - Cytokines
IL-6, IL-1α, IL-33, IL-17, IL-10, IL-8, TNFα, IFN-g… - Kinases JAKs, BTK, IRAK4, SYK, ITK, PI3Ks, RIPKs, and TPL2…
Phenotype-based Approach
We integrate the database, experimental technology and testing equipment as the foundation of target identification.
- Computational Prediction
Enquiring various bioinformatics datasets - Chemical-geneticEngineering
Assessing the relationship between gene dose and drug reaction - Affinity-based Chromatography
Purifying and examining certain components attaching to the drug.
With our mature and advantageous Affinity-based Chromatography Technology, we have successfully completed a variety of target identification projects by this classical phenotype-based strategy as the following workflow:
Cells or tissues
Proteome extract
Drug-bead or drug-tag complex
Beads or tags affinity purification
SDS-PAGE and MS
Our Advantages
One-stop services with short cycle time
Professional team with customizable studies
Timely stage reporting and whole process follow-up
Serving clients worldwide
With a wealth of experience in small molecule drug development from plenty of customized projects, our company will help you make a comprehensive experimental blueprint, make sure that every intermediate result is reliable, and escort your experiments from start to end for autoimmune diseases and inflammation. If you are interested in our services, please contact us for more detailed information.
Reference
- Ha, Jaeyoung et al. "Recent advances in identifying protein targets in drug discovery." Cell chemical biology 28,3 (2021): 394-423.